NDAORALTABLET
Approved
May 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
TRIGLIDE (fenofibrate) by Molecular Devices is acid. Approved for dyslipidemia, hypertriglyceridemia, hypercholesterolemia and 1 more indications. First approved in 2005.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIGLIDE (fenofibrate) is an oral fibrate that activates peroxisome proliferator-activated receptor α (PPARα) to treat dyslipidemia, hypertriglyceridemia, and hypercholesterolemia. It reduces triglycerides, increases HDL cholesterol, and converts small dense LDL particles into larger buoyant particles more easily cleared by the liver. The drug also reduces serum uric acid levels through increased urinary excretion.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating team restructuring and transition planning may already be underway.
Mechanism of Action
acid. The pharmacological effects of fenofibric acid in both animals and humans have been extensively studied through oral administration of fenofibrate. The lipid-modifying effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human…
Indications (4)
Worked on TRIGLIDE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.